Screening of Diastolic Dysfunction With Impedance Cardiography in Hypertensive Patients

NCT ID: NCT03209141

Last Updated: 2018-08-03

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Total Enrollment

154 participants

Study Classification

OBSERVATIONAL

Study Start Date

2015-01-02

Study Completion Date

2018-01-15

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Arterial hypertension (AHT) is responsible for important morbidity and mortality. The cardiac repercussion of AHT is usually assessed by electrocardiography and echocardiography, time-consuming, technically demanding examinations that require experienced operators, which limits their use for screening diastolic dysfunction. Alternative tools for the screening of diastolic function in hypertensive patients are needed. Impedance cardiography (IC) is presently used in the study of AHT and in the optimization of antihypertensive therapy. It seems an attractive and economical option to change the clinical approach for screening; however, its validation in well-defined populations is required to sustain its use in clinical practice. The IMPEDDANS study aims to validate IC for screening left ventricular diastolic dysfunction in outclinic patients with AHT, using functional echocardiography as the clinical standard. Descriptive and analytical study with analysis of the agreement between the diagnosis of diastolic dysfunction and its degree, as well as the parameters obtained by impedance cardiography and echocardiography in patients with AHT.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

BACKGROUND. Impedance cardiography (IC) is a complementary diagnostic test used in the study of arterial hypertension (AHT) and in the optimization of antihypertensive therapy. It is easy-to-execute, non-operator-dependent and cost-effective. It analyses and registers hemodynamic changes through the measurement of electrical resistance changes in the thorax and translates them graphically as impedance and electrocardiogram waveforms. IC has evolved in recent years, making it an attractive and economical tool, particularly in screening settings and there is extensive published literature on its usefulness. More widespread use of IC has been limited due to limitations of the studies, mostly cross-sectional, with small samples, recruiting hemodynamically stable patients and providing inconsistent estimates of accuracy and reproducibility in different settings.

AHT is responsible for high morbidity and mortality. In Portugal, according to PHYSA study, has overall prevalence of hypertension, in 2014, of 42.2% (44.4% in men, 40.2% in women). The progression of hypertensive heart disease involves myocardial fibrosis and changes in left ventricular geometry that precedes functional changes. Diastolic dysfunction is part of this continuum, and despite the growing recognition of its importance, it is generally undervalued because of the difficulty in its diagnosis and the absence of effective therapies. This reinforces the importance of finding alternative tests that provide important information for an initial assessment of diastolic function in hypertensive patients.

This study intends to define the importance and usefulness of IC in the evaluation of LV diastolic dysfunction in patients with AHT.

METHODS. Study Design. This is a validation study of a diagnostic method used in a new context, comparing it with the diagnostic method currently used for this effect in usual clinical practice. Its purpose is to determine the positive predictive value, negative predictive value, sensitivity and specificity of the presence of the D wave, the isovolumetric relaxation time, the systolic time ratio (STR) and thoracic fluid content (TFC) by IC, for the diagnosis of LV diastolic dysfunction (LVDD). To study the relationship between LV geometry, hemodynamic profile, diastolic dysfunction and its degree (confirmed by echocardiography) in hypertensive patients with diastolic dysfunction. We chose to perform a concordance study between IC and echocardiography, the validated , non-invasive test used for the clinical diagnosis of LVDD as well as for the characterization of hypertensive cardiopathy.

To calculate the sample size we considered the primary endpoint (concordance of the diagnosis of diastolic dysfunction between IC and echocardiography). Thus, considering a hypothesized positive predictive value of 70 ± 5% of the parameters obtained by IC, 77 individuals are estimated to be able to verify the expected positive predictive value with 95% confidence. Since the prevalence of diastolic dysfunction in patients with AHT estimated to be approximately 50% in most studies, the sample size is doubled for 154 hypertensive patients.

Evaluation. Participants will be systematically assessed by IC and echocardiography, with a maximum interval of 8 days between them, to obtain the parameters to be used in the validation and concordance studies. To ensure that both tests are performed under similar conditions, evaluations matching variations greater than 10% in BP or variations in excess of 5% in HR will not be considered. These patients should, if possible, repeat one of the exams. If they maintain variations greater than those defined, they should be excluded from the study.

Baseline Data. Ambulatory clinic protocol for patients followed for AHT require clinical evaluation, blood test, electrocardiogram and, eventually, 24 hours ambulatory blood pressure monitoring (AMBP). Data regarding the comorbidities and pharmacotherapy will be collected. Anthropometric data regarding adiposity and vital signs will be registed and body mass index calculated as weight (kg) divided by height (m) squared. Blood pressure will be measured in a quiet room with semiautomatic device (Omron HEM-907XL, Omron Healthcare, Bannockburn, Illinois, USA) with an appropriate cuff according with the established recommendations. If necessary 24 hours ABPM will be performed using an ABPM device - Spacelabs model 90207 (Issaquah, Washington, USA) also according with current guidelines. Electrocardiogram will be performed per institutional protocol with a Page Writer TC 30, Philips, Eindhoven, Netherlands. The analytical screening evaluation includes complete blood count, haematocrit, urinalysis, urine microalbumin, serum sodium, potassium, creatinine (estimated or measured glomerular filtration rate \[GFR\]), and calcium, uric acid, glycated haemoglobin, lipid profile following a 9- to 12-hour fast (total cholesterol, high-density lipoprotein cholesterol, low-density lipoprotein cholesterol, and triglycerides), thyroid-stimulating hormone and brain natriuretic peptide.

Impedance Cardiography. Impedance cardiography will be carried out in a single centre by a cardiopneumology technician with Niccomo continuous cardiac output monitor (Medis, GmbH, Ilmenau, Germany). This equipment uses the technique of four electrodes, two of current application and two others that detect the changes of voltage. As the current amplitude is constant, the voltage detected is proportional to the tissue impedance. Patients must present with fasting of 6 hours but must take their antihypertensive drugs and the examination is carried out in 4 phases after an initial 5 minutes hemodynamic stabilization period: 1. supine position I - 20 minutes continuous recording; 2. 70º orthostatism -with the help of the tilting table for 10 min in continuous recording; 3. tilt-back at 0º; 4. supine position II - 10 min continuous recording. The examination is interrupted if there is syncope or pre-syncope; dizziness, nausea and malaise associated with poorly tolerated hypotension and / or bradycardia; pain / precordial discomfort; ECG ST segment changes; Systolic blood pressure \> 210mmHg.

Transthoracic Echocardiography. Transthoracic echocardiography will be performed in Vivid E9 and S5 devices (GE Healthcare, Chicago, Illinois, USA) by experienced cardiologists. The exam will be held in the echocardiography laboratories of two reference centers. To ensure uniformity of evaluation and correct evaluation all exams will be reviewed by a second cardiologist with experience in the technic. In order to define and grade diastolic dysfunction will be recorded left atrium volume index, the velocities E, A, septal e´, lateral e´, deceleration time (DT), isovolumetric relaxation time (IRVT), atrial reverse velocity (Ar) and E/A ratio variation with Valsalva maneuver (last two will only valued if the patient cooperates and if the images obtained have the necessary quality for analysis) as recommended by 2009 guidelines. Left ventricular geometry will be defined accordingly with international recommendations.

Analytic Statistics. The diagnostic validity parameters will be calculated with 95% confidence intervals, using logistic regression models. The positive and negative predictive values will be calculated and the sensitivity and specificity will be estimated; receiver-operator curves (ROC) will also be analysed, with the calculation of the area under the curve. Diagnostic models with more than one parameter will be tested, using multivariable analysis, logistic and linear regression. For the analysis of agreement between the parameters obtained by ICG and echocardiography, the Bland-Altman method will be used with STATA® and R-project® software.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Hypertension Diastolic Dysfunction

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Observational Model Type

CASE_CONTROL

Study Time Perspective

CROSS_SECTIONAL

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Diastolic dysfunctional hypertension

Patients with confirmed arterial hypertension and diastolic dysfunction by echocardiographic diastolic function evaluation

Diastolic function evaluation

Intervention Type DIAGNOSTIC_TEST

Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)

Non diastolic dysfunctional hypertension

Patients with confirmed arterial hypertension and without diastolic dysfunction by echocardiographic diastolic function evaluation

Diastolic function evaluation

Intervention Type DIAGNOSTIC_TEST

Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Diastolic function evaluation

Diastolic function assessed by impedance cardiography (test to be validated) is compared with the assessment by echocardiography (clinical standard)

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* grade 2 or 3 hypertension (systolic blood pressure ≥ 160 mmHg and/or with diastolic blood pressure values ≥ 100 mmHg) and/or with resistant hypertension (as defined by European Society of Cardiology

Exclusion Criteria

* pregnancy,
* height less than 120 cm or more than 230 cm,
* weight less than 30 kg or greater than 155 kg,
* heart failure II-IV NYHA,
* heart rate (HR) less than 50 bpm or greater than 110 bpm,
* atrial fibrillation or flutter,
* \> 3 premature ventricular contractions per hour,
* complete left bundle branch or atrioventricular block,
* severe valvulopathies,
* constrictive pericarditis,
* hypertrophic and restrictive cardiomyopathy,
* prior history of ischemic heart disease and/or segmental kinetics alterations assessed by echocardiography,
* left ejection fraction \< 50%,
* poor echocardiographic window ,
* pacemaker.
Minimum Eligible Age

18 Years

Maximum Eligible Age

75 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Centro Hospitalar de Lisboa Central

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Rodrigo N Leão, MD

Role: PRINCIPAL_INVESTIGATOR

Centro Hospitalar de Lisboa Central

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Consulta de Hipertensão Arterial, UF Medicina 1.4 do Hospital São José, Centro Hospitalar de Lisboa Central

Lisbon, , Portugal

Site Status

Consulta de Risco Vascular da Unidade Funcional Medicina 1.2, Hospital São José, Centro Hospitalar de Lisboa Central

Lisbon, , Portugal

Site Status

Núcleo de Hipertensão Arterial, Consulta de Medicina do Hospital de Santa Marta, Centro Hospitalar de Lisboa Central

Lisbon, , Portugal

Site Status

Countries

Review the countries where the study has at least one active or historical site.

Portugal

References

Explore related publications, articles, or registry entries linked to this study.

Ventura HO, Taler SJ, Strobeck JE. Hypertension as a hemodynamic disease: the role of impedance cardiography in diagnostic, prognostic, and therapeutic decision making. Am J Hypertens. 2005 Feb;18(2 Pt 2):26S-43S. doi: 10.1016/j.amjhyper.2004.11.002.

Reference Type BACKGROUND
PMID: 15752931 (View on PubMed)

Ferrario CM, Basile J, Bestermann W, Frohlich E, Houston M, Lackland DT, Smith RD, Wise DL. The role of noninvasive hemodynamic monitoring in the evaluation and treatment of hypertension. Ther Adv Cardiovasc Dis. 2007 Dec;1(2):113-8. doi: 10.1177/1753944707086095.

Reference Type BACKGROUND
PMID: 19124400 (View on PubMed)

Taler SJ. Individualizing antihypertensive combination therapies: clinical and hemodynamic considerations. Curr Hypertens Rep. 2014 Jul;16(7):451. doi: 10.1007/s11906-014-0451-y.

Reference Type BACKGROUND
PMID: 24806735 (View on PubMed)

Bour J, Kellett J. Impedance cardiography: a rapid and cost-effective screening tool for cardiac disease. Eur J Intern Med. 2008 Oct;19(6):399-405. doi: 10.1016/j.ejim.2007.07.007. Epub 2008 Feb 11.

Reference Type BACKGROUND
PMID: 18848172 (View on PubMed)

Patterson RP. Fundamentals of impedance cardiography. IEEE Eng Med Biol Mag. 1989;8(1):35-8. doi: 10.1109/51.32403.

Reference Type BACKGROUND
PMID: 18238303 (View on PubMed)

Cybulski G, Strasz A, Niewiadomski W, Gasiorowska A. Impedance cardiography: recent advancements. Cardiol J. 2012;19(5):550-6. doi: 10.5603/cj.2012.0104.

Reference Type BACKGROUND
PMID: 23042327 (View on PubMed)

Cybulski G. Ambulatory impedance cardiography: new possibilities. J Appl Physiol (1985). 2000 Apr;88(4):1509-10. doi: 10.1152/jappl.2000.88.4.1509. No abstract available.

Reference Type BACKGROUND
PMID: 10819621 (View on PubMed)

Harvey S, Harrison DA, Singer M, Ashcroft J, Jones CM, Elbourne D, Brampton W, Williams D, Young D, Rowan K; PAC-Man study collaboration. Assessment of the clinical effectiveness of pulmonary artery catheters in management of patients in intensive care (PAC-Man): a randomised controlled trial. Lancet. 2005 Aug 6-12;366(9484):472-7. doi: 10.1016/S0140-6736(05)67061-4.

Reference Type BACKGROUND
PMID: 16084255 (View on PubMed)

Richard C, Warszawski J, Anguel N, Deye N, Combes A, Barnoud D, Boulain T, Lefort Y, Fartoukh M, Baud F, Boyer A, Brochard L, Teboul JL; French Pulmonary Artery Catheter Study Group. Early use of the pulmonary artery catheter and outcomes in patients with shock and acute respiratory distress syndrome: a randomized controlled trial. JAMA. 2003 Nov 26;290(20):2713-20. doi: 10.1001/jama.290.20.2713.

Reference Type BACKGROUND
PMID: 14645314 (View on PubMed)

Tang WH, Tong W. Measuring impedance in congestive heart failure: current options and clinical applications. Am Heart J. 2009 Mar;157(3):402-11. doi: 10.1016/j.ahj.2008.10.016. Epub 2008 Dec 16.

Reference Type BACKGROUND
PMID: 19249408 (View on PubMed)

Mills KT, Bundy JD, Kelly TN, Reed JE, Kearney PM, Reynolds K, Chen J, He J. Global Disparities of Hypertension Prevalence and Control: A Systematic Analysis of Population-Based Studies From 90 Countries. Circulation. 2016 Aug 9;134(6):441-50. doi: 10.1161/CIRCULATIONAHA.115.018912.

Reference Type BACKGROUND
PMID: 27502908 (View on PubMed)

Polonia J, Martins L, Pinto F, Nazare J. Prevalence, awareness, treatment and control of hypertension and salt intake in Portugal: changes over a decade. The PHYSA study. J Hypertens. 2014 Jun;32(6):1211-21. doi: 10.1097/HJH.0000000000000162.

Reference Type BACKGROUND
PMID: 24675681 (View on PubMed)

Nazario Leao R, Marques da Silva P. Diastolic dysfunction in hypertension. Hipertens Riesgo Vasc. 2017 Jul-Sep;34(3):128-139. doi: 10.1016/j.hipert.2017.01.001. Epub 2017 Mar 6.

Reference Type BACKGROUND
PMID: 28268171 (View on PubMed)

Krzesinski P, Gielerak GG, Kowal JJ. A "patient-tailored" treatment of hypertension with use of impedance cardiography: a randomized, prospective and controlled trial. Med Sci Monit. 2013 Apr 5;19:242-50. doi: 10.12659/MSM.883870.

Reference Type BACKGROUND
PMID: 23558598 (View on PubMed)

Ganau A, Devereux RB, Roman MJ, de Simone G, Pickering TG, Saba PS, Vargiu P, Simongini I, Laragh JH. Patterns of left ventricular hypertrophy and geometric remodeling in essential hypertension. J Am Coll Cardiol. 1992 Jun;19(7):1550-8. doi: 10.1016/0735-1097(92)90617-v.

Reference Type BACKGROUND
PMID: 1534335 (View on PubMed)

Nagueh SF, Appleton CP, Gillebert TC, Marino PN, Oh JK, Smiseth OA, Waggoner AD, Flachskampf FA, Pellikka PA, Evangelisa A. Recommendations for the evaluation of left ventricular diastolic function by echocardiography. Eur J Echocardiogr. 2009 Mar;10(2):165-93. doi: 10.1093/ejechocard/jep007. No abstract available.

Reference Type BACKGROUND
PMID: 19270053 (View on PubMed)

Lang RM, Badano LP, Mor-Avi V, Afilalo J, Armstrong A, Ernande L, Flachskampf FA, Foster E, Goldstein SA, Kuznetsova T, Lancellotti P, Muraru D, Picard MH, Rietzschel ER, Rudski L, Spencer KT, Tsang W, Voigt JU. Recommendations for cardiac chamber quantification by echocardiography in adults: an update from the American Society of Echocardiography and the European Association of Cardiovascular Imaging. Eur Heart J Cardiovasc Imaging. 2015 Mar;16(3):233-70. doi: 10.1093/ehjci/jev014.

Reference Type BACKGROUND
PMID: 25712077 (View on PubMed)

DeMarzo AP. Using impedance cardiography with postural change to stratify patients with hypertension. Ther Adv Cardiovasc Dis. 2011 Jun;5(3):139-48. doi: 10.1177/1753944711406770. Epub 2011 Apr 28.

Reference Type BACKGROUND
PMID: 21527444 (View on PubMed)

Mancia G, Fagard R, Narkiewicz K, Redon J, Zanchetti A, Bohm M, Christiaens T, Cifkova R, De Backer G, Dominiczak A, Galderisi M, Grobbee DE, Jaarsma T, Kirchhof P, Kjeldsen SE, Laurent S, Manolis AJ, Nilsson PM, Ruilope LM, Schmieder RE, Sirnes PA, Sleight P, Viigimaa M, Waeber B, Zannad F; Task Force Members. 2013 ESH/ESC Guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens. 2013 Jul;31(7):1281-357. doi: 10.1097/01.hjh.0000431740.32696.cc. No abstract available.

Reference Type BACKGROUND
PMID: 23817082 (View on PubMed)

Nazario Leao R, Marques Silva P, Branco L, Fonseca H, Bento B, Alves M, Virella D, Palma Reis R. Systolic time ratio measured by impedance cardiography accurately screens left ventricular diastolic dysfunction in patients with arterial hypertension. Clin Hypertens. 2017 Dec 27;23:28. doi: 10.1186/s40885-017-0084-y. eCollection 2017.

Reference Type DERIVED
PMID: 29299336 (View on PubMed)

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

CHLC.CI.165.2013

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.

Central Hemodynamics
NCT01837784 UNKNOWN